StreetInsider.com News Articles

B.Riley Starts Precigen Inc. (PGEN) at Buy

Fri, 25 Sep 2026 03:44:31 -0400

B.Riley analyst Yuan Zhi initiates coverage on Precigen Inc. (NASDAQ: PGEN) with a Buy rating and a price target of $12.00.

The analyst comments: “PGEN is a newly commercial-stage immuno-oncology company whose lead product, PAPZIMEOS, is the first and only FDA-approved therapy for adult recurrent respiratory papillomatosis (RRP). RRP is a rare disease due to HPV 6/11 that chronically impacts the airway, which is managed by repeat surgical debulking today. The August 14, 2025, approval was a traditional approval carrying no confirmatory-trial requirement. PAPZIMEOS's commercial launch is tracking ahead of recent rare oncology launches, including SpringWorks Therapeutics' (SWTX) OGSIVEO in desmoid

B.Riley Starts Precigen Inc. (PGEN) at Buy

Fri, 25 Sep 2026 03:44:31 -0400

B.Riley analyst Yuan Zhi initiates coverage on Precigen Inc. (NASDAQ: PGEN) with a Buy rating and a price target of $12.00.

Form 4 PRECIGEN, INC. For: Sep 23 Filed by: Thomasian Harry Jr.

Thu, 24 Sep 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260924/27102428.html

FDA grants Precigen platform technology designation for AdenoVerse

Mon, 21 Sep 2026 07:01:16 -0400

Precigen, Inc. (Nasdaq: PGEN) announced that the U.S. Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underlies the company's commercial product PAPZIMEOS, approved by the FDA in August 2025 for the treatment of recurrent respiratory papillomatosis in adults.

To qualify for the designation, a platform must already be used in an FDA-approved product and must be demonstrated to be well characterized, reproducible, and adaptable across multiple products without compromising quality, manufacturing, or safety. The FDA determined that the AdenoVerse platform meets these criteria and is reasonably likely to generate efficiencies in development, manufacturing, and regulatory

FDA grants Precigen platform technology designation for AdenoVerse

Mon, 21 Sep 2026 07:01:16 -0400

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Mon, 21 Sep 2026 07:00:00 -0400

Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform

GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ --

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Mon, 21 Sep 2026 07:00:00 -0400

Designation has the potential to accelerate development of current and future therapies built on Precigen's AdenoVerse platform

GERMANTOWN, Md., Sept. 21, 2026 /PRNewswire/ --

Form 4 PRECIGEN, INC. For: Aug 26 Filed by: KINDLER JEFFREY B

Fri, 28 Aug 2026 20:39:00 -0400

si-local-file:///var/storage/secattach/20260828/26999422.html

Form 4 PRECIGEN, INC. For: Aug 26 Filed by: KINDLER JEFFREY B

Fri, 28 Aug 2026 20:39:00 -0400

si-local-file:///var/storage/secattach/20260828/26999422.html

Form 144 PRECIGEN, INC. Filed by: KINDLER JEFFREY B

Wed, 26 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260826/26982403.html

Form 144 PRECIGEN, INC. Filed by: KINDLER JEFFREY B

Wed, 26 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260826/26982403.html

Form 4 PRECIGEN, INC. For: Aug 21 Filed by: AGEE NANCY H

Tue, 25 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26975839.html

Form 4 PRECIGEN, INC. For: Aug 21 Filed by: AGEE NANCY H

Tue, 25 Aug 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26975839.html

Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Lehr Donald P.

Tue, 25 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26975825.html

Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Lehr Donald P.

Tue, 25 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260825/26975825.html

Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Thomasian Harry Jr.

Tue, 25 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260825/26975818.html

Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Thomasian Harry Jr.

Tue, 25 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260825/26975818.html

Form 4 PRECIGEN, INC. For: Aug 21 Filed by: Shah Rutul R

Tue, 25 Aug 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260825/26975811.html

Form 4 PRECIGEN, INC. For: Aug 21 Filed by: Shah Rutul R

Tue, 25 Aug 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260825/26975811.html

Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Tennant Phil

Tue, 25 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260825/26975797.html

Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Tennant Phil

Tue, 25 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260825/26975797.html

Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Sabzevari Helen

Tue, 25 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260825/26975786.html

Form 4 PRECIGEN, INC. For: Aug 23 Filed by: Sabzevari Helen

Tue, 25 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260825/26975786.html

Form 144 PRECIGEN, INC. Filed by: Shah Rutul R

Tue, 25 Aug 2026 14:02:00 -0400

si-local-file:///var/storage/secattach/20260825/26973930.html

Form 144 PRECIGEN, INC. Filed by: Shah Rutul R

Tue, 25 Aug 2026 14:02:00 -0400

si-local-file:///var/storage/secattach/20260825/26973930.html